Home/ Stocks/ MYGN

Myriad Genetics Inc

MYGN XNAS

$4.29 +0.20 (+4.89%) ▲ 15-min delayed

Open

$4.13

High

$4.38

Low

$4.00

Volume

1.98M

Market Cap

$405.18M

About Myriad Genetics Inc

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 2.7K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$200.40M	$-34,100,000	$-0.36
FY 2025	$824.50M	$-365,900,000	$-3.95
Q3 2025	$205.70M	$-27,400,000	$-0.29
Q2 2025	$213.10M	$-330,500,000	$-3.57

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for MYGN yet. Check out our latest market news or earnings calendar.

Get MYGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Myriad Genetics Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.